Moonlake Immunotherapeutics Earnings

Moonlake Immunotherapeutics’s revenue fell -100% since last year same period to $0Mn in the Q4 2025. On a quarterly growth basis, Moonlake Immunotherapeutics has generated NaN% jump in its revenue since last 3-months.

Moonlake Immunotherapeutics’s net profit fell -36.89% since last year same period to $-62.43Mn in the Q4 2025. On a quarterly growth basis, Moonlake Immunotherapeutics has generated 10.47% jump in its net profits since last 3-months.

Moonlake Immunotherapeutics’s net profit margin fell -Inf% since last year same period to -Inf% in the Q4 2025. On a quarterly growth basis, Moonlake Immunotherapeutics has generated NaN% jump in its net profit margins since last 3-months.

Moonlake Immunotherapeutics’s earning per share (EPS) estimates for the current quarter stand at -0.98 - a -11.42% fall from last quarter’s estimates.

Moonlake Immunotherapeutics’s earning per share (EPS) estimates for the current year stand at -0.98.

Moonlake Immunotherapeutics’s earning per share (EPS) fell -27.78% since last year same period to -0.92 in the Q4 2025. This indicates that the Moonlake Immunotherapeutics has generated -27.78% annual rate of fall in its earning per share (EPS) in the last 4 quarters.